LOXL2 and neoplasm: Consistent with our prior findings15,31, LOXL2 knockdown (Supplementary Fig. 2a, b) or enzymatic inhibition in 344SQ tumors reduced metastatic disease (Fig. 2b), collagen crosslinking (Fig. 2c), and collagen deposition (Supplementary Fig. 2c and d) with no significant effect on primary tumor growth (Supplementary Fig. 2e).